AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 254: E349-E357, 1988;
0193-1849/88 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tillil, H.
Right arrow Articles by Polonsky, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tillil, H.
Right arrow Articles by Polonsky, K. S.

AJP - Endocrinology and Metabolism, Vol 254, Issue 3 E349-E357, Copyright © 1988 by American Physiological Society


ARTICLES

Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans

H. Tillil, E. T. Shapiro, M. A. Miller, T. Karrison, B. H. Frank, J. A. Galloway, A. H. Rubenstein and K. S. Polonsky
Department of Medicine, University of Chicago, Pritzker School of Medicine, Illinois 60637.

Insulin secretion and clearance were studied in 2 groups of 7 normal subjects who each received 25, 50, and 100 g of glucose either orally or intravenously (iv) on separate occasions. Insulin secretion rates were calculated during a 1-h base line and for 5 h after glucose administration from a two-compartmental analysis of peripheral C-peptide concentrations using individual kinetic parameters derived after iv bolus injections of biosynthetic human C-peptide. Incremental glucose areas after oral or iv glucose increased as a function of the glucose dose (P = 0.0001). Incremental insulin secretion increased with increasing doses of both oral and iv glucose (P = 0.0001). The metabolic clearance rate (MCR) of endogenous insulin was calculated as the ratio of the total area under the insulin secretion rate curve and the simultaneous peripheral insulin concentration curve. The basal MCR was 1,879.5 +/- 110.5 ml/min (mean +/- SE). The poststimulatory MCR decreased with increasing doses of both oral and iv glucose concomitant with the greater insulin secretory response (P = 0.0014). This decrease in insulin clearance was not significantly different between oral and iv administration of glucose (P = 0.495). In conclusion diminished insulin clearance may be seen after marked stimulation of insulin secretion with larger doses of oral and iv glucose.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. J. Meier, J. J. Holst, W. E. Schmidt, and M. A. Nauck
Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E849 - E856.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Campioni, G. Toffolo, L. T. Shuster, F. J. Service, R. A. Rizza, and C. Cobelli
Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study
Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E54 - E60.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. O. Larsen, B. Rolin, J. Sturis, M. Wilken, R. D. Carr, N. Porksen, and C. F. Gotfredsen
Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Gottingen minipigs in vivo
Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E670 - E677.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
G. Toffolo, M. Campioni, R. Basu, R. A. Rizza, and C. Cobelli
A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E169 - E176.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. A. Nauck, B. Baller, and J. J. Meier
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Diabetes, December 1, 2004; 53(suppl_3): S190 - S196.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
N. N. Rudovich, H. J. Rochlitz, and A. F.H. Pfeiffer
Reduced Hepatic Insulin Extraction in Response to Gastric Inhibitory Polypeptide Compensates for Reduced Insulin Secretion in Normal-Weight and Normal Glucose Tolerant First-Degree Relatives of Type 2 Diabetic Patients
Diabetes, September 1, 2004; 53(9): 2359 - 2365.
[Abstract] [Full Text] [PDF]


Home page
Clin. DiabetesHome page
K. L. Herbst and I. B. Hirsch
Insulin Strategies for Primary Care Providers
Clin. Diabetes, January 1, 2002; 20(1): 11 - 17.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Brandt, M. Katschinski, R. Arnold, K. S. Polonsky, B. Goke, and M. M. Byrne
GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve
Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E242 - E247.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online